当前位置: 首页 >> 检索结果
701. [Antisese oligonucleotide therapy for patients with castration-resistant prostate cancer].702. [Gene therapy].703. [Recent trend in the development of novel treatments based on the mechanisms of prostate cancer progression].704. [microRNA].705. [Development of promising biomarkers for prostate cancer].706. [Prognostic factors in hormone-sensitive advanced prostate cancer].707. [Disorder of signal transduction concerning carcinogenesis and progression without androgen receptor interaction in prostate cancer].708. [Alteration of androgen receptor cofactor in prostate cancer].709. [Mutation of androgen receptor].710. [Mechanism of development and progression in prostate cancer: Overview].711. [Prostate cancer and epigenetics].712. [Oncogene and tumor suppressor gene for prostate cancer].
作者: Takeshi Ueda.;Atsushi Komaru.;Jun-ryo Rii.;Masayuki Kobayashi.;Satoshi Fukasawa.
来源: Nihon Rinsho. 2016年74 Suppl 3卷60-4页 713. [Molecular biology and genetics of prostate cancer].714. [Hereditary and familial prostate cancer].
作者: Yoshitatsu Fukabori.;Nobuaki Ohtake.;Hiroshi Matsui.;Kazuhiro Suzuki.
来源: Nihon Rinsho. 2016年74 Suppl 3卷47-51页 715. [Natural history of prostate cancer--The evolutionary history of lethal clone].716. [Perspective of basic research on prostate cancer].717. [Current status and future prospects in HMGB1 and receptor researches].
High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.
718. [Association between Efficacy of Pemetrexed and EGFR Mutation Status for EGFR Mutated Lung Carcinoma].
Subgroup analysis of Japanese patients in a LUX-Lung 3 trial showed different progression-free survival(PFS) after cisplatin (CDDP) plus pemetrexed (PEM) treatment between patients in the exon 21 L858R (L858R) group (8.3 months) and the exon 19 deletion (19 del) group (3.1 months). PEM may have different efficacies in patients with L858R or 19 del.
|